Mecanismos moleculares asociados al síndrome metabólico
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoAstraZeneca (United Kingdom)-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2017
-
Inhibition of T-Cell activation by the CTLA4-Fc abatacept is sufficient to ameliorate proteinuric kidney disease
American Journal of Physiology - Renal Physiology, Vol. 312, Núm. 4, pp. F748-F759